Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?

Core Insights - Boston Scientific reported fourth-quarter 2025 adjusted earnings per share of 80 cents, a 14.3% increase year-over-year, surpassing the Zacks Consensus Estimate by 2.6% and the company's guidance of 77-79 cents [2][3] - The company's total revenue for the fourth quarter reached $5.29 billion, reflecting a 15.9% year-over-year increase, exceeding the Zacks Consensus Estimate by 0.4% [4] Financial Performance - Adjusted earnings per share for the full year 2025 was $3.06, a 21.9% increase from 2024, also exceeding the Zacks Consensus Estimate by 0.7% [3] - The gross margin expanded by 172 basis points to 69.6%, while adjusted operating margin increased by 180 basis points to 24% [11] Revenue Breakdown - Fourth-quarter revenues by region showed a 17% increase in the United States, 12.4% in EMEA, 15.2% in Asia Pacific, and 15.9% in Latin America and Canada [6] - The MedSurg segment generated $1.81 billion in revenue, up 15.9% year-over-year, while the Cardiovascular segment reported $3.48 billion, an 18.2% increase [8][10] Future Outlook - For 2026, Boston Scientific anticipates net sales growth of approximately 10.5-11.5% on a reported basis, with adjusted earnings per share expected in the range of $3.43-$3.49 [12] - The first quarter of 2026 is projected to see revenue growth of approximately 10.5-12% on a reported basis, with adjusted earnings expected between 78-80 cents per share [13] Market Position - Boston Scientific holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [16] - The company has a Growth Score of B and a Momentum Score of C, placing it in the middle 20% for value investors [15]